Results 81 to 90 of about 4,590 (196)

Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2523-2530, May 2025.
Abstract Aims In Soli‐CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin‐naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%–13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy) increased time in range (TIR; primary ...
Viral N. Shah, Terry Dex, Luigi Meneghini, Amélie Rodrigues, William H. Polonsky   +4 more
wiley   +1 more source

Glucose metabolism and oscillatory behavior of pancreatic islets [PDF]

, 2005
A variety of oscillations are observed in pancreatic islets.We establish a model, incorporating two oscillatory systems of different time scales: One is the well-known bursting model in pancreatic beta-cells and the other is the glucose-insulin feedback model which considers direct and indirect feedback of secreted insulin.
arxiv   +1 more source

iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN studies

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2593-2600, May 2025.
Abstract Aims To evaluate early glycaemic control (glycated haemoglobin [HbA1c] < 7.0% [<53.0 mmol/mol], fasting plasma glucose [FPG] ≤ 7.0 mmol/L or postprandial glucose [PPG] ≤ 10.0 mmol/L) with iGlarLixi versus insulin glargine 100 U/mL (Gla‐100) in Asian people with suboptimally controlled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs) in ...
Lulu Song, Xiaoyong Yuan, Shan Huang, Yawei Zhang, Felipe Lauand, Zhini Wang, Jie Zhang, Qin Du, Lei Kang, Wenying Yang, Xiaohui Guo   +10 more
wiley   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐SWITCH study

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2730-2739, May 2025.
Abstract Aims To assess the efficacy and safety of switching from premixed insulin to a once‐daily, fixed‐ratio combination of insulin glargine 100 U/mL + lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D). Methods In this phase 4, 24‐week, single‐arm study, participants switched from once‐daily or twice‐daily premixed insulin to iGlarLixi ...
Martin Haluzík, Katarzyna Cypryk, Agustina Alvarez, Felipe Lauand, Valérie Corp dit Genti, Okan Sefa Bakiner, Soo Lim   +6 more
wiley   +1 more source

A Pilot Study of a Comparison of Glycemic Control in Critically Ill Patients

Journal of Health Science and Medical Research (JHSMR), 2010
Objective: To compare glycemic control in the critically ill patients between a single dose of subcutaneous injection of insulin glargine and a continuous intravenous infusion of regular insulin.
Rungsun Bhurayanontachai, Piyada Kongkamol, Chanon Kongkamol   +2 more
doaj  

Antiproliferative MCR peptides block physical interaction of insulin with retinoblastoma protein (RB) in human lung cancer cells [PDF]

arXiv, 2007
Fifteen years ago, a structural analysis of the hormone insulin and the retinoblastoma tumor suppressor protein (RB) revealed that they may physically interact with one another. Subsequently, an RB peptide corresponding to the proposed RB binding site for insulin was found to recognize full-length insulin in vitro.
arxiv  

Time in range—A new gold standard in type 2 diabetes research?

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2342-2362, May 2025.
Abstract Glycated haemoglobin (HbA1c) is currently the gold standard outcome measure for type 2 diabetes trials. Time in range is a continuous glucose monitoring (CGM) metric defined as the proportion of time in euglycemia (3.9–10.0 mmol/L) and may be valuable not only in type 1 diabetes clinical trials but also as an endpoint in type 2 diabetes trials.
Ashni Goshrani, Rose Lin, David O'Neal, Elif I. Ekinci   +3 more
wiley   +1 more source

A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2750-2767, May 2025.
Abstract Aim To understand the existing literature on the epidemiology and clinical, humanistic, and economic burden of diabetic ketoacidosis (DKA) in people living with type 2 diabetes mellitus (T2DM). Materials and Methods MEDLINE, Embase and the Cochrane library were systematically searched for studies published between 1 January 2014 and 14 ...
Carol Wysham, Anila Bindal, Fleur Levrat‐Guillen, Desislava Kostadinova, Yeesha Poon   +4 more
wiley   +1 more source

Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2810-2821, May 2025.
Abstract Aims To understand real‐world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in the United States. Materials and Methods This retrospective, observational study used Optum's de‐identified Market Clarity database (index date: first‐observed tirzepatide claim ...
Emily R. Hankosky, Chanadda Chinthammit, Alexandra Meeks, Ahong Huang, Jennifer M. Ward, Donna Mojdami, Theresa Hunter Gibble   +6 more
wiley   +1 more source

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. [PDF]

, 2000
Mauro Lepore, Simone Pampanelli, Carmine G. Fanelli, Francesca Porcellati, Luca Bartocci, Angelo Di Vincenzo, Cristina Cordoni, E Costa, P. Brunetti, Geremia B. Bolli   +9 more
openalex   +1 more source